not affect receptor expression, cytokine production, NF -κB activation, chemotactic responses, or apoptosis. The authors suggested that high levels of P -selectin on the surface of activated platelets or binding of multiple platelets by monocytes may be required to trigger monocyte activation via PSGL -1. 29 Platelet activation is evident in acute PE and correlates with the severity of right ventricular dysfunction. 30 There is also a considerable body of evidence supporting the correlation of platelet function with platelet volume. Thompson et al 31 reported a more rapid and more complete aggregation with increased platelet size and suggested that large platelets may be functionally more important than smaller ones. The authors showed that large platelets had greater density, higher enzymatic activity of lactate dehydrogenase, a higher number of dense bodies per platelet and per cubic micron of platelet volume. Finally, they demonstrated greater serotonin uptake and release with increased thrombin concentrations. Moreover, Mannucci et al 32 observed that platelet aggregation appeared to selectively involve large platelets.
Increased values of the mean platelet volume (MPV) in patients with acute PE were observed. 33 - 35 Sevuk et al 34 reported that serial measurements of MPV and platelet distribution width (PDW), as well as percent change in MPV and PDW, appear to be useful markers for predicting the occurrence of acute PE in patients with a first episode of acute proximal DVT. Varol et al 33 also revealed that MPV was independently correlated with right ventricular dimension. Moreover, Kostrubiec et al 36 found MPV to be an independent predictor of early death in acute PE.
Considering the above evidence concerning the role of monocytes and large platelets, as well as the platelet-monocyte crosstalk, in thrombus formation, we aimed to assess the value of the peripheral blood monocyte to large platelet ratio (MLPR) for the diagnosis of PE in patients with AECOPD. To our knowledge, this is the first report analyzing this novel parameter.
PATIENTS AND METHODS
This was a retrospective analysis of de -identified data collected in the digital database of AECOPD of the Department of Pneumology and Allergy and the Department of General and Oncological Pulmonology of the Medical University of Lodz in Łódź, Poland. Therefore, there was no need to obtain the approval of an ethics committee.
The study was conducted in a population of patients admitted to the hospital between November 2007 and May 2017 due to AECOPD and suspicion of PE. All included patients had moderate to high probability of PE according to the Wells score and the revised Geneva score.
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A plasma D -dimer value below 500 μg/l was considered negative; however, in cases of a high clinical probability of PE, such a result did not exclude deaths from COPD in the year following the episode of PE. 13, 14 Due to the similar clinical presentation, and the fact that routine laboratory tests do not allow the exclusion or confirmation of acute PE,
15,16
the detection of PE with coexisting AECOPD is still a diagnostic challenge. Therefore, the development of a new diagnostic tool that would help in the diagnosis of PE in this patient group may be of special interest for everyday clinical practice.
Physiologically, monocytes play a crucial role in innate immunity and the development of tissue macrophages and dendritic cells. They are also important for coagulation processes. 17 Monocytes appear to be the major source of blood tissue factor, which is the key element of the coagulation cascade and occurs in 2 forms: as a transmembrane protein, which can be activated during vascular wall damage and exposure of subendothelial tissues to circulating elements in blood, and as a splice variant in a soluble form. 17 During AECOPD, monocytes can express increased amounts of tissue factor following stimulation by hypoxia, C -reactive protein, or lipopolysaccharides, among others.
18-21
McGilvray et al 22 reported that tissue factor can also be expressed by monocytes that have transmigrated across the endothelium to the sites of extravascular inflammation, and that it acts both to focus and amplify the inflammatory response. The authors suggested that an extravascular focus of infection or inflammation can promote both intravascular thrombosis and extravascular fibrin deposition during the process of adhesion and transmigration across the endothelial barrier. Monocyte -bound tissue factor has also been found to be present at elevated levels in patients with deep vein thrombosis (DVT). 23 Moreover, Granger et al 24 reported that highly purified human blood monocytes are capable of extracellular trap release in response to several stimuli, and that these monocyte extracellular traps demonstrate procoagulant activity, which broadens the range of the thrombogenic properties of monocytes.
Another important mechanism linking monocytes and inflammation with thrombus generation is the platelet -monocyte crosstalk leading to monocyte-platelet aggregation. P -selectin is a transmembrane protein that resides within the α -granule membrane of unstimulated platelets 25 and is translocated to the surface membrane on platelet activation.
26, 27 Platelets can bind via P -selectin to the leukocyte receptor P -selectin glycoprotein ligand 1 (PSGL -1). 28 Although both platelet-monocyte and other peripheral blood leukocyte-platelet interactions are mediated by PSGL -1 and P -selectin, a more prolonged and stable binding to monocytes was observed. 29 Platelet activation seems to be the key aspect of the pathophysiology of monocyte-platelet aggregates. Bournazos et al 29 reported that binding of activated platelets triggers proinflammatory responses in monocytes, while the binding of unstimulated platelets did Continuous data were presented as mean with SD or median with interquartile range (IQR), depending on data distribution. The area under the receiver operating characteristic (ROC) curve (AUC) was presented as the result and 95% confidence interval (CI), while the accuracy of the qualitative test parameters was presented as point estimates or percentages (sensitivity and specificity) and 95% CIs.
ROC analyses were preformed to measure the accuracy of the MLPR in comparison with CTPA results and to identify the cutoff value for the MLPR for further analyses. An AUC greater than 0.9 was considered as excellent; 0.8 to 0.9, as very good; 0.7 to 0.8, as good; 0.6 to 0.7, as average; and below 0.6, as poor. 38 Two -way tables were created for the diagnosis of PE by CTPA using the MLPR as a diagnostic test to assess the apparent prevalence, true prevalence, sensitivity, specificity, positive and negative predictive values, likelihoods, and diagnostic accuracy. The ROC curves for the MLPR measurement and D -dimer test were compared using the DeLong test. Agreement between the diagnosis of PE by MLPR and CTPA thresholds was assessed by the Cohen κ coefficient.
Continuous variables were compared using the Welch's t test for normally distributed data and the Wilcoxon rank sum test with continuity correction for data with a nonnormal distribution. Categorical variables were compared using the χ 2 test with Yates correction, if appropriate. For a more accurate analysis of factors influencing the MLPR value, a multivariable logistic regression was used. A P value of less than 0.05 was considered significant. a patient from further examination. The diagnosis of PE was confirmed by computed tomography pulmonary angiography (CTPA). The interpretation was made by a senior radiologist, and PE was diagnosed when embolic material was directly visualized or when vessel truncation implied the presence of occlusion.
Only patients with the results of full blood count and white blood cell differentiation, measured before the treatment of suspected PE, were included. Venous blood was collected by venipuncture into tubes with ethylenediaminetetraacetic acid as an anticoagulant. The sample was immediately transferred to a laboratory and was examined with an automated hematology analyzer. The cell count and size were assessed using the electrical impedance method.
The exclusion criteria were as follows: a history of any myeloproliferative disorder, myelofibrosis, Glanzmann thrombasthenia, May-Hegglin anomaly, Bernard-Soulier syndrome, suspicion of disseminated intravascular coagulation, blood transfusion in the last 2 months, and administration of any anticoagulant drug at a therapeutic dose. Additionally, patients with acute coronary syndrome, pulmonary edema, or pneumothorax were excluded, as well as those who required either invasive or noninvasive ventilation, and were directly transferred to an intensive care unit.
The MLPR was calculated as follows: MLPR = (monocyte absolute count) / LPC × 100%, where LPC is the large platelet count. LPC can be calculated by multiplying the platelet count (PLT) by the platelet-large-cell ratio (PLCR): LPC = (PLT × PLCR) / 100. The results were analyzed using the R software for MacOS (R Core Team [2016] . R: A language and environment for statistical computing; R Foundation for Statistical Computing, Vienna, Austria). RESULTS A total of 101 patients were enrolled to the study (56 men and 45 women; median age, 72 years; range, 37-94 years). The flow chart of patient selection for inclusion in the study is presented in FIGURE 1.
In 24 patients (23.76%), PE was confirmed by CTPA. In 70.83% of the patients, central PE was detected, and in 29.17%, peripheral PE (including subsegmental PE in 57.14%). The baseline clinical data and comorbid diseases according to the occurrence of PE are presented in TABLES 1 and 2, respectively. Smoking history was not associated with the occurrence of PE (88% of former smokers and 12% of active smokers; χ 2 <0.001, P = 1.0). No difference was found between sexes (χ 2 = 0.11, P = 0.7). The MLPR measurement demonstrated excellent accuracy in comparison with CTPA results: the AUC was 0.945 (95% CI, 0.904-0.986) (FIGURE 2A) .
The D -dimer test showed poor accuracy in comparison with CTPA results: the AUC was 0.564 (95% CI, 0.414-0.713). The DeLong test revealed a difference between the ROC curves for the MLPR measurement and D -dimer test (Z = 4.9063, P <0.001) (FIGURE 2B). an excellent accuracy in diagnosing PE, using CTPA results as a reference. The MLPR was characterized by a good profile of the variables describing the accuracy of qualitative test parameters, including high sensitivity and specificity, in the analyzed population. We hypothesize that the MLPR indirectly reflects the role of the relationships between platelets and monocytes in thrombus formation; it may be a surrogate marker of thrombosis and assist the differential diagnosis of PE in patients with AECOPD. Additionally, because the absolute monocyte count and PLCR are commonly measured in clinical practice, the MLPR may be routinely calculated and any additional costs would therefore be negligible. This makes this parameter a cost -effective biomarker that could be widely used in everyday clinical practice. In our study, patients with PE showed decreased platelet count and plateletcrit with a significantly lower LPC. It is possible that when large platelets are involved in thrombus formation, their numbers in circulating blood decrease. This observation also complies with evidence for a more rapid and complete aggregation with an increased platelet size, and shows that platelet aggregation may selectively involve large platelets.
31, 32 On the other hand, we observed a higher absolute monocyte count in patients with PE. Similar observations were reported by Rezende et al 39 in venous thrombosis. These observations, as well as evidence concerning the role of monocytes 17-24 and platelet-monocyte crosstalk 17,28 in thrombus formation, constitute the rationale for developing the MLPR and assessing its usefulness for diagnostic purposes.
In contrast, the D -dimer test appeared to be of limited value in diagnosing PE in the analyzed population, and studies concerning the use of D -dimer in AECOPD are inconsistent. Li et al 40 The MLPR of 1.654% showed the best sensitivity (100%; 95% CI: 79.6-100) and specificity (85.7%; 95%CI: 75.9-92.6). This cutoff value yielded 24 true positive results (23.8%), 11 false positive results (10.9%), and 66 true negative results (65.3%).
The apparent prevalence was 0. The clinical data of patients according to the cutoff value of 1.654% for the MLPR are presented in TABLE 3.
Of the included patients, 21.31% suffered from infective AECOPD, of whom 65.57% had coexisting pneumonia. Neither the infective nature of AECOPD nor pneumonia seemed to affect the MLPR values (W = 978, P = 0.09 and W = 370, P = 0.3, respectively). Moreover, we did not show differences in a similar analysis according to the cutoff value of the MLPR (χ 2 = 2.73, P = 0.1 and χ 2 = 0.71, P = 0.4 respectively). In a qualitative analysis, the χ 2 test identified only DVT to be associated with higher MLPR values (χ 2 = 6.4, P = 0.01) (TABLE 4). The multivariable logistic regression analysis demonstrated that type 2 diabetes (P = 0.03), congestive heart failure (P = 0.04), and chronic kidney disease (P = 0.01) were factors influencing the MLPR values. DISCUSSION The results of our study confirm the utility of a new diagnostic tool that may assist the diagnosis of PE in patients with AECOPD. The MLPR measurement demonstrated has limited diagnostic value in excluding PE in the population of patients with AECOPD. This can be explained mainly by the fact that age, smoking status, or comorbidities specific to this group of patients may also influence D -dimer values. 41 In our study, age and smoking status were found to have no significant effect on the MLPR; however, the multivariable logistic regression analysis demonstrated the significant effect of type 2 diabetes, congestive heart failure, and chronic kidney disease. This finding needs to be confirmed in a prospective study. If our results are replicated, the use of the MLPR might have significant clinical implications. The common overuse of CTPA for diagnosing PE, particularly in emergency departments, is controversial.
42 Besides the obvious benefits associated with the increasing rate of PE diagnoses, the decreased number of CTPA procedures may result in a lower occurrence of potential complications such as radiation harms, allergies, and contrast -induced nephropathy. In addition, the increasing costs and potential delays to care 43-45 underline the need for an additional, reported a frequency of PE of 10.3% in a series of 522 patients with AECOPD, and recommended that patients with AECOPD admitted to the hospital should be considered for the presence of PE if they demonstrate the following risk factors: immobilization lasting 3 days or longer, lower extremity edema, and D -dimer levels of 2000 μg/l or higher. Fruchter et al 7 revealed higher D -dimer levels in patients with venous thromboembolism (VTE)/PE than in those with AECOPD alone; however, this study was a retrospective analysis of a relatively small group of patients, and VTE/PE was excluded by imaging modalities only in patients with positive D -dimer test results. Hypothetically, it is also possible that VTE/PE was present and not detected in some patients with low D -dimer levels.
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simple, and inexpensive diagnostic tool to assist in the diagnosis of PE in everyday clinical practice. We believe that the MLPR might be a reliable tool in a differential diagnosis of PE in patients with AECOPD. Moreover, it might prove useful in decision making about using CTPA in this patient group. It might also help reduce the extent of CTPA overuse and thus the risk of potential complications. Finally, it might be cost -effective and contribute to reducing potential delays to care delivery. Our study has several limitations. First, as a retrospective study, it did not include data on potential confounding factors. Although we assessed the utility of the MLPR in the diagnosis of PE, we hypothesize that the increased values of this parameter are not specific to the presence of thrombus in lung arteries only, but that they are associated with thrombotic incidents in general. This issue should be addressed in future research. Another issue is that after the exclusion of PE, our patients did not undergo a further diagnostic workup for other types of thrombotic events. Another significant limitation is a high prevalence of subsegmental PE (57.14% of the patients with peripheral PE), while an unequivocal diagnosis of acute PE may be reached when thromboemboli are visualized at least in segmental arteries on CTPA.
To sum up, the current work is the first report to assess the utility of the MLPR in the diagnosis of PE. The MLPR measurement appears to be a reliable, simple, inexpensive, and widely available test that may help in the differential diagnosis of PE in patients with AECOPD. However, burdened by significant limitations, the study should be considered only as hypothesis -generating about the potential routine use of the MLPR in the diagnosis of PE in daily clinical practice. CONTRIBUTION STATEMENT AJB and PG contributed to study concept and design; AJB, KK, MC, and JM -D were involved in data acquisition. All authors contributed to analysis, interpretation of data, and drafting of the manuscript. All authors critically revised the manuscript and approved the version to be published.
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